EMA Recommends Extension of Indications for Serplulimab By Ogkologos - April 22, 2026 286 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of patients with oesophageal squamous cell carcinoma and non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to Rare Cancer Care Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy MOST POPULAR Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab... January 26, 2022 First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable... July 5, 2021 Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab... July 9, 2021 Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over... September 22, 2026 Load more HOT NEWS TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... A Combination of Amivantamab and Lazertinib Shows Durable Clinical Activity in... Prostate Cancer Prevention and Finasteride: A Conversation with NCI’s Dr. Howard... Immunotherapy after Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer
